Clinical trial
Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration…
NCT05369000 · Lava Therapeutics, Industry · Terminated
Key facts
| NCT number | NCT05369000 |
|---|---|
| Title | Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer |
| Official title | A Phase 1 Open-label Trial to Evaluate the Safety, Tolerability, PK, PD, Immunogenicity, and Antitumor Activity of LAVA-1207, a PSMA-targeting Bispecific γδ-T Cell Engager, Alone or With Low Dose Interleukin-2 or Pembrolizumab, in Patients With Therapy Refractory mCRPC |
| Lead sponsor | Lava Therapeutics, Industry |
| Collaborators | Merck Sharp & Dohme LLC Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Metastatic Castration Resistant Prostate Cancer |
| Intervention type | Biological |
| Interventions | LAVA-1207, LAVA-1207 plus Pembrolizumab |
| Enrollment | 96 |
| Start date | Jan 17, 2022 |
| Primary completion | Jun 18, 2025 |
| Completion | Jun 18, 2025 |
| First posted | May 11, 2022 |
| Last update posted | Aug 1, 2025 |
| Countries | Netherlands, Spain, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: